Tag: CD70
First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...
Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366), an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.
Ambrx and Novocodex to Jointly Develop and Commercialize 2nd Antibody-drug Conjugate
Novocodex Biopharmaceuticals, a subsidiary of Zhejiang Medicine, and Ambrx, a privately-held clinical stage biopharmaceutical company, have confirmed that the companies will jointly develop and...
